Open AccessAfatinib restrains K-RAS–driven lung tumorigenesis
Author(s) -
Herwig P. Moll,
Klemens Pranz,
Mónica Musteanu,
Beatrice Grabner,
Natascha Hruschka,
Julian Mohrherr,
Petra Aigner,
Patricia Stiedl,
Luka Brčić,
Viktória László,
Daniel Schramek,
Richard Moriggl,
Robert Eferl,
Judit Moldvay,
Katalin Dezső,
Pedro P. LópezCasas,
Dagmar Stoiber,
Manuel Hidalgo,
Josef Penninger,
Maria Sibilia,
Balázs Győrffy,
Mariano Barbacid,
Balázs Döme,
Helmut Popper,
Emilio Casanova
Publication year - 2018
Publication title -
science translational medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.aao2301
Subject(s) - carcinogenesis , afatinib , cancer research , lung , erbb , lung cancer , signal transduction , medicine , biology , chemistry , receptor , epidermal growth factor receptor , microbiology and biotechnology , cancer , gefitinib
K-RAS –mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven lung tumorigenesis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom